Devonian Health Group Reports Cease Trade Order
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has received a failure to file cease trade order (FFCTO) from the Autorité des Marchés Financiers (AMF) due to delayed filing of required interim financial documents for the period ended January 31, 2025.
The FFCTO prohibits all trading of company securities in Canada, including trades through the TSX Venture Exchange. The required documents include interim financial statements, management's discussion and analysis, and related filings that were due by April 1, 2025.
Trading suspension became effective April 8, 2025. The company continues normal business operations and will seek FFCTO revocation once the required filings are submitted. Trading reinstatement requires both FFCTO revocation and Exchange approval following a compliance review.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) ha ricevuto un ordine di cessazione del commercio per mancata presentazione (FFCTO) dall'Autorité des Marchés Financiers (AMF) a causa del ritardo nella presentazione dei documenti finanziari intermedi richiesti per il periodo terminato il 31 gennaio 2025.
L'FFCTO vieta tutte le negoziazioni dei titoli della società in Canada, comprese quelle attraverso la TSX Venture Exchange. I documenti richiesti includono i bilanci finanziari intermedi, la discussione e analisi della direzione e le relative comunicazioni, che dovevano essere presentati entro il 1° aprile 2025.
La sospensione delle negoziazioni è entrata in vigore l'8 aprile 2025. La società continua le normali attività operative e richiederà la revoca dell'FFCTO non appena i documenti richiesti saranno presentati. La riattivazione delle negoziazioni richiede sia la revoca dell'FFCTO sia l'approvazione della Borsa dopo una revisione di conformità.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) ha recibido una orden de suspensión de comercio por incumplimiento de presentación (FFCTO) de la Autorité des Marchés Financiers (AMF) debido a la demora en la presentación de los documentos financieros interinos requeridos para el período finalizado el 31 de enero de 2025.
La FFCTO prohíbe todas las operaciones con valores de la empresa en Canadá, incluidas las transacciones a través de la Bolsa de Valores TSX Venture. Los documentos requeridos incluyen estados financieros interinos, análisis y discusión de la gerencia, y presentaciones relacionadas que debían entregarse antes del 1 de abril de 2025.
La suspensión de las operaciones entró en vigor el 8 de abril de 2025. La empresa continúa con sus operaciones normales y solicitará la revocación de la FFCTO una vez que se presenten los documentos requeridos. La reanudación de las operaciones requiere tanto la revocación de la FFCTO como la aprobación de la Bolsa tras una revisión de cumplimiento.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF)는 2025년 1월 31일 종료된 기간에 대한 필수 중간 재무 문서 제출 지연으로 인해 Autorité des Marchés Financiers (AMF)로부터 제출 실패 거래 중지 명령(FFCTO)을 받았습니다.
FFCTO는 캐나다 내 회사 증권의 모든 거래를 금지하며, TSX 벤처 거래소를 통한 거래도 포함됩니다. 요구된 문서에는 중간 재무제표, 경영진 토의 및 분석, 그리고 2025년 4월 1일까지 제출되어야 했던 관련 서류들이 포함됩니다.
거래 정지는 2025년 4월 8일부터 효력이 발생했습니다. 회사는 정상적인 영업을 계속하며, 필요한 서류가 제출되는 대로 FFCTO 해제를 요청할 예정입니다. 거래 재개는 FFCTO 해제와 거래소의 승인, 그리고 준수 검토를 모두 필요로 합니다.
Devonian Health Group (TSXV : GSD ; OTCQB : DVHGF) a reçu un ordre de cessation de négociation pour défaut de dépôt (FFCTO) de l'Autorité des Marchés Financiers (AMF) en raison du retard dans le dépôt des documents financiers intermédiaires requis pour la période clôturée au 31 janvier 2025.
L'FFCTO interdit toutes les transactions sur les titres de la société au Canada, y compris les échanges via la Bourse TSX Venture. Les documents requis comprennent les états financiers intermédiaires, la discussion et l'analyse de la direction, ainsi que les dépôts associés, qui devaient être soumis avant le 1er avril 2025.
La suspension des négociations est entrée en vigueur le 8 avril 2025. La société poursuit ses activités normales et demandera la levée de l'FFCTO dès que les documents requis seront déposés. La reprise des négociations nécessite à la fois la levée de l'FFCTO et l'approbation de la Bourse après un examen de conformité.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) hat von der Autorité des Marchés Financiers (AMF) eine Anordnung zum Handelsstopp aufgrund versäumter Einreichung (FFCTO) erhalten, da die erforderlichen Zwischenfinanzberichte für den Zeitraum bis zum 31. Januar 2025 verspätet eingereicht wurden.
Die FFCTO untersagt den Handel mit Wertpapieren des Unternehmens in Kanada, einschließlich Transaktionen über die TSX Venture Exchange. Die erforderlichen Dokumente umfassen Zwischenfinanzberichte, die Management-Diskussion und -Analyse sowie zugehörige Einreichungen, die bis zum 1. April 2025 fällig waren.
Die Handelssperre trat am 8. April 2025 in Kraft. Das Unternehmen führt seine normalen Geschäftstätigkeiten fort und wird die Aufhebung der FFCTO beantragen, sobald die erforderlichen Unterlagen eingereicht wurden. Die Wiederaufnahme des Handels erfordert sowohl die Aufhebung der FFCTO als auch die Genehmigung der Börse nach einer Compliance-Prüfung.
- None.
- None.
The FFCTO was issued as a result of the delay in filing the Company’s interim financial statements for the fiscal period ended January 31, 2025, its management’s discussion and analysis for the fiscal period ended January 31, 2025, and related filings (collectively, the “Required Interim Filings”). Under Regulation 51-102 respecting Continuous Disclosure Obligations, the Required Annual Filings were required to be made no later than April 1, 2025. The FFCTO will remain in place until such time as the Required Annual Filings, along with any additional filings which may be required at such time, are filed and the AMF subsequently revokes the FFCTO.
As a result of the FFCTO, trading in the Company’s securities on the Exchange has also been suspended effective as of April 8, 2025. Reinstatement to trading will occur only when the FFCTO is revoked, and the Exchange has concluded its reinstatement review to ensure the Company has satisfactorily complied with Exchange requirements.
The Company will continue to operate in the normal course of business, fulfilling its commercial contracts and obligations and intends to immediately apply for a revocation of FFCTO as soon as its Required Interim Filings are duly filed.
About Devonian
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Group L.P., focused on selling prescription pharmaceutical products in
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in
For more information, visit www.groupedevonian.com
Cautionary Note Regarding Forward-Looking Statements
All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to FFCTO, the revocation of the FFCTO by the AMF, if any, the filling, in due time, if any, by the Company of its Interim Required Fillings, and, generally, the above “About Devonian” and “About Altius” paragraphs, which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of
Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414298057/en/
Devonian Health Group Inc.
Mr. Luc Grégoire
President and CEO
Dr. André P. Boulet, PhD
Chairman, COO and CSO
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com
Source: Devonian Health Group Inc.
FAQ
Why was Devonian Health Group (DVHGF) issued a cease trade order in April 2025?
When will DVHGF stock resume trading after the April 2025 suspension?
What financial documents did DVHGF fail to file by the April 2025 deadline?
Does the April 2025 cease trade order affect DVHGF's business operations?
What markets are affected by DVHGF's April 2025 trading suspension?
